奥西默替尼
肺癌
T790米
抗药性
医学
酪氨酸激酶
癌症研究
表皮生长因子受体抑制剂
吉非替尼
表皮生长因子受体
药理学
化学
埃罗替尼
受体
内科学
生物
生物化学
遗传学
作者
Matin Shaikh,Yashodeep Shinde,Rahul H. Pawara,Malleshappa N. Noolvi,Sanjay Javerilal Surana,Iqrar Ahmad,Harun Patel
标识
DOI:10.1021/acs.jmedchem.1c00876
摘要
The pyrimidine core-containing compound Osimertinib is the only epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) from the third generation that has been approved by the U.S. Food and Drug Administration to target threonine 790 methionine (T790M) resistance while sparing the wild-type epidermal growth factor receptor (WT EGFR). It is nearly 200-fold more selective toward the mutant EGFR as compared to the WT EGFR. A tertiary cystein 797 to serine 797 (C797S) mutation in the EGFR kinase domain has hampered Osimertinib treatment in patients with advanced EGFR-mutated non-small-cell lung cancer (NSCLC). This C797S mutation is presumed to induce a tertiary-acquired resistance to all current reversible and irreversible EGFR TKIs. This review summarizes the molecular mechanisms of resistance to Osimertinib as well as different strategies for overcoming the EGFR-dependent and EGFR-independent mechanisms of resistance, new challenges, and a future direction.
科研通智能强力驱动
Strongly Powered by AbleSci AI